Skip to main content

Neuroendocrine Tumours

  1. In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [166Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT). The ai...

    Authors: Sander C. Ebbers, Tessa Brabander, Margot E. T. Tesselaar, Johannes Hofland, Manon N. G. J. A. Braat, Frank J. Wessels, Maarten W. Barentsz, Marnix G. E. H. Lam and Arthur J. A. T. Braat
    Citation: EJNMMI Research 2022 12:7
    Content type: Original research Published on:

  2. Pheochromocytomas (PCCs) and paragangliomas (PGLs), together referred to as PPGLs, are rare chromaffin cell-derived tumors. They require timely diagnosis as this is the only way to achieve a cure through surge...

    Authors: Hermine Mohr, Alessia Foscarini, Katja Steiger, Simone Ballke, Christoph Rischpler, Franz Schilling and Natalia S. Pellegata
    Citation: EJNMMI Research 2021 11:121
    Content type: Review Published on:

  3. In the case of extravasation of radioactive drugs used in peptide-receptor radionuclide therapy of neuroendocrine tumors, or in radionuclide therapy in general, rapid action is important to reduce or avoid com...

    Authors: Anne Kirstine Arveschoug, Anne Charlotte Bekker, Peter Iversen, Henrik Bluhme, Gerda Elisabeth Villadsen and Peter Frøhlich Staanum
    Citation: EJNMMI Research 2020 10:68
    Content type: Case report Published on:

  4. 68Ga-labelled peptides targeting somatostatin receptor 2 (SSTR2) have demonstrated encouraging results in managing patients with neuroendocrine tumours (NETs). In addition to metal chelation, bifunctional chelat....

    Authors: Yuxiao Xia, Chengrun Zeng, Yanhong Zhao, Xinyi Zhang, Zibo Li and Yue Chen
    Citation: EJNMMI Research 2020 10:36
    Content type: Original research Published on:

  6. Positron emission tomography (PET) imaging with 68Gallium labeled somatostatin analogues (68Ga-DOTA-SSA) plays a key role in neuroendocrine tumor management. The impact of patient size on PET image quality is not...

    Authors: Christina P. W. Cox, Marcel Segbers, Laura H. Graven, Tessa Brabander and Daniëlle M. E. van Assema
    Citation: EJNMMI Research 2020 10:27
    Content type: Original research Published on:

  7. [18F]AmBF3-TATE is a somatostatin agonist that selectively binds to somatostatin receptor subtype 2 (SSTR2). For clinical translation, pharmacokinetics, radiation dosimetry, and acute toxicity of [18F]AmBF3-TATE ...

    Authors: Joseph Lau, Jinhe Pan, Etienne Rousseau, Carlos F. Uribe, Sudhakara Reddy Seelam, Brent W. Sutherland, David M. Perrin, Kuo-Shyan Lin and François Bénard
    Citation: EJNMMI Research 2020 10:25
    Content type: Original research Published on: